Study explores access to psychedelics for therapeutic use: patient perspectives highlight stigma and physician unfamiliarity as barriers

Psychedelic access for therapeutic use can stall before patients reach regulated care, because stigma and communication gaps with physicians discourage open discussion. Researchers led by Michelle St. Pierre surveyed about 800 adults who use psychedelics, finding that most reported barriers to access and only a minority had discussed psychedelic use with their doctor. Even when conversations happened, relatively few patients reported their physician recommending psychedelics, and many described worse satisfaction with the communication, as well as feeling discriminated against. In Canada, legal access requires physician assessment and an application through Health Canada's Special Access Program, creating a high threshold. The study points to physician education, guidelines, and improved patient-clinician communication as key steps as policies evolve for conditions such as depression, anxiety, and PTSD.